Oncolytic virus therapy: A new era of cancer treatment at dawn Oncolytic virus therapy is perhaps the next major breakthrough in cancer treatment following the success in immunotherapy using immune checkpoint inhibitor... H Fukuhara,Y Ino,T Todo - 《Cancer Science》 被引量: 85发表: 2016年 ...
2024年美国临床肿瘤学会突破峰会(ASCO Breakthrough)于2024年8月8日-8月10日在日本横滨盛大召开。本届峰会以“点亮癌症治疗的提升之路(Shining a Light on Advances in Cancer Care)”为主题,在鼻咽癌领域,马骏院士牵头开展的评估卡瑞利珠单抗...
In the future, CAR-T cell therapy is expected to become an important cancer treatment, and may provide new ideas and strategies for individualized immunotherapy. The present review provides a comprehensive overview of the principles, clinical applications, therapeutic efficacy and chall...
本届峰会以“点亮癌症治疗的提升之路(Shining a Light on Advances in Cancer Care)”为主题,在鼻咽癌领域,马骏院士牵头开展的评估卡瑞利珠单抗辅助治疗高危局晚期鼻咽癌的临床III期DIPPER研究大放异彩。继成功入选2024 ASCO LBA重磅研究,并被纳入Best of ASCO(优秀论文)后,时隔两月,DIPPER研究重磅入选ASCO Break...
由美国临床肿瘤学会(ASCO)主办的ASCO Breakthrough会议于2024年8月8日~10日在日本横滨举办。本次大会以“Shining a Light on Advances in Cancer Care”为主题,将邀请全球肿瘤学领域的专家学者,分享肿瘤领域研究进展,共同推动全球肿瘤治疗水平的进一步提升。
由美国临床肿瘤学会(ASCO)主办的ASCO Breakthrough会议于2024年8月8日~10日在日本横滨举办。本次大会以“Shining a Light on Advances in Cancer Care”为主题,将邀请全球肿瘤学领域的专家学者,分享肿瘤领域研究进展,共同推动全球肿瘤治疗水...
Researchers atOxford Universityand theUniversity of Birminghamhave made a major breakthrough in cancer treatment by creating the first human bone marrow “organoids” that accurately replicate the key features of human bone marrow. The technology, which is the subject of a patent application filed ...
2. ASCO breakthrough to highlight advances in esophageal, nasopharyngeal, lung, cancers new treatment approaches help improve survival, quality of life. News release. ASCO. August 5, 2024. Accessed August 6, 2024.https://society.asco.org/about-asco/press-center/news-releases/asco-breakthrough-...
Breakthrough pain in cancer patients: Pathophysiology and treatment The treatment of pain shows a special challenge in the ambulatory and stationary treatment of various medical departments. A multifactorial design has to b... S Mercadante,E Arcuri - 《Cancer Treatment Reviews》 被引量: 690发表: ...
(FDA) in 2001 for the treatment of chronic myelogenous leukemia (CML), a rare form ofcancerthat affects certain types of white blood cells. Since its initial approval, Gleevec has also been approved for use in patients with several types of gastrointestinal tumors. Currently, scientists continue...